The Rebate Trap
Your Money. Their Leverage.
Executive Brief
Here’s a scenario playing out in conference rooms across the country right now.
An employer discovers their PBM is underperforming. Costs are rising. Transparency is lacking. The fiduciary committee agrees: it’s time to explore other options. Then someone asks the obvious question: “What happens to our rebates if we leave?”
The answer stops the conversation. The contract says rebates are forfeited upon early termination. Money the employer already earned, from prescriptions already filled, for employees already served. Gone.
This is the rebate trap. Your money, used as leverage against you.
We’ve previously covered why rebates harm participants: they inflate list prices, increase out-of-pocket costs for your sickest employees, and create conflicts of interest in formulary design.
But there’s another dimension we’re seeing in contract after contract: rebates aren’t just bad economics. They’re a governance weapon. And they’re being used to constrain your fiduciary decision-making.
The Double Whammy
Let’s be candid. Rebates are a bad deal.
Research from the USC Schaeffer Center found a nearly dollar-for-dollar relationship between rebates and list prices: for every $1 increase in rebates, a drug’s list price rises by $1.17. You’re paying more on the front end to receive money back on the back end.
The net effect? Your sickest employees, those with high-deductible plans paying coinsurance based on list price, absorb the inflation. The rebate flows to the plan. The cost flows to the patient.
That’s the first hit.
The second hit comes when you try to act on this knowledge. You want to switch PBMs, renegotiate terms, or dispute a fee. And then you discover: the rebates you thought you’d earned are being held hostage.
Termination forfeiture clauses. Dispute-triggered withholding. Clawback provisions on “guaranteed” amounts. These aren’t edge cases. They’re standard practice in many PBM contracts.
You overpay on the front end. They hold your money on the back end. And if you try to leave, they keep what’s yours.
What We’re Seeing in Contracts
Through our Contract X-Ray analysis, we’ve identified several rebate-related provisions constraining fiduciary action. The mechanisms are more sophisticated than most employers realize.
Termination Forfeiture
Many contracts specify rebates earned but unpaid are forfeited if the employer terminates before the contract end date. The money was generated by your employees’ prescriptions. It belongs to your plan. But the contract says otherwise.
The Compounding Exit Penalty
Termination forfeiture is the visible cost. Some contracts add a second layer that runs in the opposite direction. In one contract we reviewed, the PBM retains unpaid rebates on exit and may seek pro-rata reimbursement of credits and allowances already received. The employer who discovers a problem in year one and acts on it doesn’t just forfeit future rebates. They may write a check on the way out. Two financial penalties. Two directions. The trap works both ways.
Dispute-Triggered Withholding
The framing matters here, and most contracts go much further than “billing disputes.”
In one negotiated contract we reviewed, the withholding condition was expanded from “delinquent in undisputed claims” in the original to “compliance with the terms” and “good financial standing” in the renegotiated version. The shift looks minor on paper. The implications are not. Any alleged breach of any contract term can now justify withholding rebates. Dispute a formulary decision. Challenge a network access fee. Request documentation on a questionable charge. Any of these could qualify.
The chilling effect isn’t limited to billing. It covers everything.
And here’s what makes this especially significant: it happened during a negotiation. The employer walked away believing they’d improved the contract. On termination flexibility, they had. On rebate protections, the renegotiated version was worse than the original. This is why provision-by-provision contract review matters more than headline terms.
Clawback Provisions
“Guaranteed” rebate amounts often come with clawback language tied to utilization thresholds, formulary changes, or contract duration. If you leave in Year 2 of a 3-year contract, you may owe back rebates already received. The guarantee becomes a trap.
From The Sublime To The Ridiculous
Even when contracts allow claims audits, rebate agreements are frequently excluded. You can audit what the PBM paid the pharmacy. You cannot audit what the PBM received from the manufacturer. The most opaque part of the relationship is the part with the most money.
But in the contracts we’ve reviewed, some mechanisms go further than exclusion.
In one contract, the audit carve-out isn’t a scope limitation at all. The employer’s auditor is permitted to review manufacturer and rebate administrator agreements. The auditor is simply prohibited, by contract, from reporting what they found back to the employer. The confidentiality agreement the auditor must sign explicitly includes the phrase “including to Client.” Your auditor, retained by you, paid by you, reviews the manufacturer agreements and cannot tell you what’s in them.
That’s not a gap in audit coverage. It’s a perversion of the audit relationship.
In a second contract, the mechanism is structural rather than contractual. The PBM prohibits auditors from copying any documents during the review. At the same time, the PBM is entitled to review the auditor’s handwritten notes before they leave the premises. The PBM sees what your auditor found before you do. There’s no usable documentary record. The audit produces a supervised visit, not an independent verification.
These clauses survive because they’re designed to be skimmed and overlooked.
“Audit rights” appears in the section heading. The confidentiality language reads like standard boilerplate. The phrase “including to Client” sits in the middle of a subordinate clause and doesn’t announce itself. Your eyes move on. Stop and parse it and the absurdity registers immediately.
Your auditor, reviewing manufacturer agreements on your behalf, cannot tell you what they found. You paid for an audit. You received a procedure. The findings belong to the party you were auditing.
The only employer who signs that clause is one who hasn’t read it carefully.
Because an employer who reads it and signs it anyway has a different problem, one that looks less like oversight and more like a documented decision to avoid receiving information they’d be obligated to act on. Either way, the PBM’s position is the same: you had rights, you exercised them, you raised no objections.
The pattern is consistent: rebates are structured to limit your options, and audit provisions are structured to protect that structure.
The Hidden Costs Beyond Forfeiture
The governance constraints are clear once you see them. But rebates carry additional hidden costs undermining fiduciary oversight.
Formulary Distortion
PBMs are incentivized to favor high-rebate drugs over clinically equivalent lower-cost alternatives. A $500 drug with a 40% rebate generates more PBM revenue than a $100 drug with no rebate, even though the second option costs the plan less. Rebate maximization does not equal cost minimization.
Conflict Documentation
When your PBM’s compensation is tied to rebate volume, every formulary decision is suspect. Are they recommending Drug A because it’s best for participants, or because it generates the highest rebate? The structure itself creates a conflict nearly impossible to disprove.
Exit Barriers
Multi-year rebate “guarantees” create switching costs. The structure is designed to make leaving expensive. And expensive exits mean fiduciaries tolerate arrangements they’d otherwise end.
The Fiduciary Problem
ERISA requires fiduciaries to act solely in the interest of plan participants. But how can you act solely in their interest when your own plan’s money is being used as leverage against you?
- A fiduciary who can’t terminate a failing vendor without forfeiting earned rebates, and potentially repaying credits already received, is constrained.
- A fiduciary who can’t dispute questionable fees without risking withheld rebates on any alleged contract breach is constrained.
- A fiduciary who can’t receive auditor reviews is operating blind in a different and more insidious way than simple scope exclusion.
These constraints aren’t accidents. They are features of a contracting model designed to protect PBM revenue, not participant interests.
CAA 2026 addresses part of this problem. The law requires 100% rebate pass-through and audit rights for rebate agreements. But those provisions don’t take effect until 2029. And they won’t apply to contracts signed today unless you negotiate them in now.
The question is whether you’re willing to act.
What to Do First Thing Monday
- Pull your PBM contract and search for “rebate.” Identify any forfeiture, clawback, or withholding provisions tied to early exit. Then look for credit and allowance repayment obligations. Know what you’d lose, and what you might owe, if you left tomorrow.
- Read your rebate withholding trigger carefully. If the condition extends beyond payment delinquency to “compliance with the terms” or “good financial standing,” any contract dispute puts your rebates at risk. That changes the negotiation calculus on everything.
- Review your audit rights and what the auditor can report back. Confirm whether your contract allows auditing of manufacturer rebate agreements. Then confirm your auditor’s confidentiality obligations. If those obligations extend to you, you don’t have an audit right. You have audit theater.
- Submit your contract for a Contract X-Ray analysis. Email support@nautilushealth.org. We’ll score your contract against fiduciary-aligned and legal standards to identify where rebate-related terms constrain your options including mechanisms that look like protections until you read the fine print.
In Closing
Rebates were sold as savings. For many employers, they’ve become handcuffs.
The money you earned from your employees’ prescriptions should serve your plan, not constrain your decisions. When a vendor uses your own money as leverage against you, that’s a governance failure, not a benefit structure.
CAA 2026 will eventually require full rebate pass-through and audit rights. But “eventually” is 2029. The contract you sign this year will run through that deadline. Make sure it protects participants, not PBM revenue.
Here’s to clearer thinking, stronger plans, and better outcomes for the people who rely on us.
All the best,
P.S. Next week: how collective benchmarking changes the negotiation dynamic. You can’t negotiate what you can’t compare. We’ll show you what employers are learning when they pool contract data and why PBMs resist it.
Subscribe & Share
🔗 Subscribe: Was this newsletter forwarded to you? Signup to receive The Health Plan Compliance Advantage every Monday.
📤 Share: If this newsletter helped clarify something that matters to your organization, forward it to your CEO, CFO, or General Counsel. The fiduciary conversation often starts when leadership sees the governance gap.
💸 SPECIAL OFFER: Newsletter subscribers receive 10% off any Validation Institute service. Use code FIDUCIARY10 at checkout.
────────────────────────────────────────
A Note of Appreciation
Barbara Delaney is an accomplished entrepreneur and visionary financial leader responsible for shaping the fiduciary transformation in the retirement industry. She’s now bringing those lessons to healthcare as the founder of SS/RBA A Fiduciary Oversight Company and as a trusted board advisor to the Nautilus Health Institute.
Don’t be a bystander. Change the status quo and reap the benefits of The Health Plan Compliance Advantage. Schedule an introductory call with us.
